While gastroesophageal reflux disease is a common comorbidity in idiopathic pulmonary fibrosis (IPF), treatment with a proton pump inhibitor does not appear to have any bearing on mortality and hospitalization outcomes among IPF patients, according to real-world data.
A recent study has shown notable characteristics of patients with chronic obstructive pulmonary disease (COPD) in advanced stages, which include decreased body mass index (BMI), fat-free body mass, hand grip strength, and respiratory and skeletal muscle functions.
The convolutional neural network (CXR-LC) model has successfully pinpointed smokers who are at increased risk for incident lung cancer beyond Centers for Medicare & Medicaid Services (CMS) eligibility and using information commonly available in the electronic medical record (EMR), reports a study.
A short-term course of oral corticosteroid medication does not appear to improve disease control in patients with moderate to severe persistent asthma initiating treatment with inhaled corticosteroid-and-long-acting beta agonist (ICS-LABA).
Short-term treatment with acetazolamide appears beneficial to patients with either central or obstructive sleep apnoea, exerting favourable effects on the apnoea-hypopnoea index and several patient-centred outcomes, including sleep quality and subjective symptoms, as shown in a study.
Among patients with COVID-19, those with underlying respiratory diseases, particularly chronic obstructive pulmonary disorder (COPD), and tobacco users are likely to have severe outcomes, according to the results of a systematic review and meta-analysis.
Children with gastro-oesophageal reflux disease (GERD) are at heightened risk of developing asthma, and those with asthma are prone to develop GERD, according to a study, which suggests that the two conditions have a bidirectional relationship.
Gefapixant, a first-in-class non-narcotic, oral P2X3 receptor antagonist, significantly reduces cough frequency in patients with refractory or unexplained chronic cough, according to two COUGH* studies presented at ERS 2020.
Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.
Almost three-quarters of adverse events (AEs) related to medication errors in over-the-counter (OTC) cough and cold medications (CCMs) for paediatrics required evaluation by healthcare facility and majority of the cases were due to dosing errors, a surveillance study has found, highlighting the need for interventions to mitigate medication errors.